<DOC>
	<DOCNO>NCT00534027</DOCNO>
	<brief_summary>Part 1 complete . Part 2 multi-center , randomize , double-blind , placebo-controlled , phase 2 segment commence upon identification maximum tolerate dose part 1 . The Primary objective Part 2 study estimate efficacy combination carboplatin paclitaxel . Subjects randomize 1:1:1 ratio 1 3 treatment arm . Subjects 3 arm receive 6 cycle paclitaxel/carboplatin ( dose schedule part 1 ) combination either AMG 655 maximum tolerate dose ( Arm 1 ) , AMG 655 low dose ( Arm 2 ) , AMG 655 placebo ( Arm 3 ) IV Q3W . Randomization stratify ECOG ( 0 1 ) disease stage ( IIIb IV/recurrent ) .</brief_summary>
	<brief_title>A Phase 1b/2 Study AMG 655 Combination With Paclitaxel Carboplatin First-Line Treatment Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Disease Related Histologically cytologically confirm nonsmall cell lung cancer . Subjects must advance nonsmall cell lung cancer define stage IIIB malignant pleural effusion stage IV recurrent disease . Planning receive 6 cycle chemotherapy Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Demographic Men woman &gt; 18 year age Ethical Adequate Hematological , renal , hepatic coagulation function General Plan begin protocol specific therapy &lt; 7 day enrollment/randomization Disease Related Untreated symptomatic central nervous system metastasis . Subjects history brain metastasis eligible definitive therapy administer ( surgery and/or radiation therapy ) , plan treatment brain metastasis subject clinically stable corticosteroid least 14 day enrollment/randomization . Prior chemotherapy follow : Any prior chemotherapy advance nonsmall cell lung cancer Any prior adjuvant chemotherapy nonsmall cell lung cancer &lt; 52 week prior enrollment/randomization . Adjuvant chemotherapy complete &gt; 52 week prior randomization permit . Any prior chemoradiation . Central ( chest ) radiation therapy &lt; 28 day prior randomization , radiation therapy peripheral lesion &lt; 14 day prior enrollment/randomization Other abnormal medical condition Documented myocardial infarction unstable/uncontrolled cardiac condition History arterial thrombosis , pulmonary embolus , deep vein thrombosis hemorrhagic disorder Major surgical procedure &lt; 30 day prior enrollment/randomization yet recover prior major surgery , Minor surgical procedure &lt; 7 day prior enrollment/randomization yet recover prior minor surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>AMG 655</keyword>
</DOC>